Moderna Gives Specifics of its Phase 3 COVID-19 Vaccine Trial

Moderna released details yesterday of a planned phase 3 trial of its COVID-19 vaccine candidate, mRNA-1273.

The Massachusetts-based drugmaker said it has finalized the protocol for the trial based on FDA feedback and expects to begin dosing next month. The trial is expected to enroll 30,000 participants in the U.S.

Moderna has also completed enrollment of the first cohort of healthy adults ages 18 to 54 in a phase 2 study of the vaccine, as well as a cohort of adults ages 55 years and older. — Jordan Williams